dalpiciclib
jiangsu hengrui pharmaceuticals
['breast', 'anastro', 'vance', 'dawna-2', 'letrozole', 'dalpiciclib', 'medsir']
dalpiciclib added to letrozole/anastrozole in the 1l setting significantly improved pfs in patients with hr+/her2- advanced breast cancer (median, 30.6 months in dalp group vs. 18.2 months in placebo group). data from phase 3 dawna-2 trial shared by dr. binghe xu. #esmo2022 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM